SARS CoV-2 infection among patients using immunomodulatory therapies

Kevin L Winthrop; Amanda E Brunton; Susan Beekmann; Philip Polgreen; John Baddley; Kenneth G Saag; Cassandra Calabrese; Leonard Calabrese; Philip C Robinson; Zachary S Wallace; Jeffrey R Curtis

doi:10.1136/annrheumdis-2020-218580

Article info

Letter

SARS CoV-2 infection among patients using immunomodulatory therapies

Authors

Kevin L Winthrop School of Public Health, Oregon Health & Science University, Portland, Oregon, USA Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA PubMed articles Google scholar articles
Amanda E Brunton School of Public Health, Oregon Health & Science University, Portland, Oregon, USA PubMed articles Google scholar articles
Susan Beekmann Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA PubMed articles Google scholar articles
Philip Polgreen Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA PubMed articles Google scholar articles
John Baddley Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA PubMed articles Google scholar articles
Kenneth G Saag Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articles Google scholar articles
Cassandra Calabrese Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA PubMed articles Google scholar articles
Leonard Calabrese Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA PubMed articles Google scholar articles
Philip C Robinson Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia PubMed articles Google scholar articles
Zachary S Wallace Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA PubMed articles Google scholar articles
Jeffrey R Curtis Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA PubMed articles Google scholar articles
the COVID-19 Study Team
Google scholar articles

Correspondence to Kevin L Winthrop, School of Public Health, Oregon Health and Science University, Portland OR 97239, USA; winthrop{at}ohsu.edu

View Full Text

Citation

Winthrop KL, Brunton AE, Beekmann S the COVID-19 Study Team, et al

SARS CoV-2 infection among patients using immunomodulatory therapies

Annals of the Rheumatic Diseases 2021;80:269-271.

Publication history

Received July 14, 2020
Revised July 22, 2020
Accepted July 25, 2020
First published August 5, 2020.

Online issue publication

January 12, 2021

Article Versions

Previous version (12 January 2021).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password